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Three recent screens use siRNAs to identify host genes that are critical for HIV-1 replication. These 
screens have uncovered hundreds of human genes not previously known to be commandeered 
by the virus during infection. Although some caveats remain, this screening approach opens up a 
new landscape of viral-host interactions for future exploration.With their short life cycle and high mutation frequency, viruses 
can adapt quickly to make maximal use of any host proteins 
that might promote their replication. Viruses are likely to 
exploit critical cellular functions and so may serve as a means 
to characterize the host cell machinery. Indeed, viruses have 
historically led to the discovery or characterization of the cellu-
lar machinery for many processes including membrane fusion, 
DNA replication at specific origins, RNA capping and splicing, 
and internal ribosomal entry during mRNA translation. Recent 
advances in genomics and RNA interference methods have 
led several laboratories to conduct whole-genome surveys to 
identify the entire set of cellular genes that can affect virus rep-
lication—the cellular or host “virome.” Three such surveys, all 
targeting host genes needed for the replication of HIV-1, have 
recently been reported (Brass et al., 2008; König et al., 2008; 
Zhou et al., 2008). The results of these studies are surprisingly 
different, suggesting that the devil may be in the details.
The first screen (Brass et al., 2008), reported in Science, 
was performed in cultured human HeLa cells engineered to 
express CD4, the essential receptor for HIV-1 entry, and a 
β-galactosidase reporter gene responsive to tat, the major 
viral transactivator protein. Pools of short-interfering RNAs 
( siRNAs), four per gene, were used to transfect the HeLa cells 
72 hr before they were infected with the replication-competent 
IIIB isolate of HIV-1. Forty-eight hours after virus infection, the 
cells were fixed and scored for the presence of the HIV-1 capsid 
protein p24 to monitor the efficiency of early events of infec-
tion, namely virus entry, reverse transcription, integration, and 
viral gene expression. The culture supernatants, which con-
tain any viruses that were released, were removed and used to 
infect fresh cells, thus allowing Brass et al. to monitor the yield 
of infectious virions from the siRNA-treated cells. This yield 
was determined by the level of tat-activated β-galactosidase 
reporter gene expression in the cells 48 hr after infection. Of the 
more than 21,000 siRNA pools (and thus genes) tested, Brass 
et al. identified 273 genes whose depletion inhibited either p24 
production or β-galactosidase activation by more than 2 stan-
dard deviations from the mean values (a ~2- to 3-fold greater 
inhibition relative to the controls). Remarkably, 237 of the 273 
genes were not known to be involved in HIV-1 replication. 
The functions of these genes span virtually all aspects of cell 
physiology, and, in principle, they define the host proteins most 
important for HIV-1 replication. They encode components of the nuclear pore complex (NPC) and the Mediator complex 
required for RNA polymerase II-driven transcription, as well as 
proteins required for transport to the Golgi, protein glycosyla-
tion, and autophagy.
Brass et al. also performed preliminary characterizations of 
three of the genes identified in the siRNA screen, each involved 
in a distinct cellular process. Depletion of Rab6, a regulator of 
retrograde protein transport to the Golgi, blocked early stages 
of virus infection without affecting expression of the viral 
receptors CD4 and CXCR4 or tat protein function in host cells. 
Rab6 depletion seemed to specifically inhibit membrane fusion 
mediated by the envelope protein of HIV-1 and the CD4 virus 
receptor, implicating Rab6 as a new player in this process. 
Indeed, Rab6 depletion did not block infection by pseudotyped 
virions that utilize vesicular stomatitis virus G (VSV-G) enve-
lope proteins instead of those of HIV-1. Like Rab6, depletion 
of Transportin 3-SR2 (TNPO3), a nuclear import factor for ser-
ine/arginine-rich (SR) substrates, also potently blocked early 
stages of infection. Unlike Rab6, TNPO3 depletion blocked 
infection after virus reverse transcription but before virus inte-
gration, strongly suggesting that it plays a role in nuclear tar-
geting of the virus. Depletion of the third gene examined, the 
Mediator transcription activation complex component Med28, 
did not affect provirus formation. Med28 depletion specifically 
blocked HIV-1 gene expression but not gene expression of the 
closely related murine leukemia viruses (MuLVs), suggesting a 
special need for the Mediator complex in HIV-1 genome tran-
scription.
In the second study by König et al. (2008) published in a recent 
issue of Cell, the authors used SV40 T antigen- and adeno virus 
E1A-transformed cultured human 293T cells instead of HeLa 
cells. To test for susceptibility to infection, a luciferase reporter 
gene was delivered to the cells using a replication-defective 
pseudotyped HIV-1 virus utilizing VSV-G envelope proteins 
instead of HIV envelope proteins. Thus, the screen only tested 
for genes involved in early events of infection; HIV-1 envelope-
mediated entry and all late events were not scored. For com-
parison, luciferase reporter genes delivered by Moloney murine 
leukemia virus and adeno-associated virus were also tested. In 
the screen, cells were transfected with siRNAs targeting 20,000 
genes, with about six siRNAs targeted to each gene. Forty-eight 
hours after siRNA treatment, the cells were infected with HIV-1 
and were assayed for luciferase expression 24 hr later. König et Cell 135, October 31, 2008 ©2008 Elsevier Inc. 417
Table 1. Comparison of the Three siRNA Knockout Screens
Host Cell Line Time of siRNA Treatment Virus Challenge Time of Scoring Post-infection Readout # of Filtered Hits
Brass et al. HeLa (CD4+, 
β-gal reporter)
72 hr Live HIV-1 (III B) 48 hr; 48 hr in new cells p24 (CA);  reporter 
 activation
273
König et al. 293T 48 hr HIV-1 luc 
 vector, VSV-G 
 pseudotyped
24 hr Luc reporter 295
Zhou et al. HeLa (CD4+, 
β-gal reporter)
24 hr Live HIV-1  
(HXB2 isolate)
48 hr; 96 hr β-gal reporter 
activation
224al. scored as positive hits all genes whose depletion resulted 
in a greater than 45% inhibition of luciferase expression, indi-
cating a decrease in virus infectivity. In addition, they examined 
by yeast two-hybrid protein-protein interactions other genes 
whose products were linked to these positive hits. In all, König et 
al. composed a list of more than 2400 candidate host cell genes 
involved in HIV-1 infectivity. These genes were then put through 
an elaborate series of filters that removed those candidates that 
also affected infection by the control viruses or killed the host 
cells when depleted. Genes that had shared functions with other 
hits, or were present in yeast two-hybrid host-virus interaction 
databases, as well as those that were coexpressed with CD4 
and coreceptors, were ranked higher as candidates. Using this 
filtering and ranking process, König et al. pared down the list to 
~800 genes. This list was further narrowed down to 295 genes 
whose depletion by siRNA inhibited HIV-1 infection by more than 
45% in the original screen. The final set of genes consisted of a 
densely connected network that could be subdivided by func-
tion into a handful of groups.
König et al. partially characterized the genes they identi-
fied to determine the steps of the viral life cycle affected by 
their depletion. Some of these genes blocked infection before 
reverse transcription, whereas others altered the kinetics of 
DNA synthesis. In these classes, many of the genes encoded 
cytoskeletal proteins (likely to be involved in the intracellular 
movement of the viral reverse transcription complex), nucleic 
acid-binding proteins (plausibly interacting with reverse tran-
scriptase), components of the ubiquitination/proteasome 
pathway (possibly required for virus particle uncoating), and, 
surprisingly, components of the DNA-damage response. 
Depletion of other genes including the nuclear pore complex 
component Nup153, the nuclear transport factor RANBP2, and 
TNPO3 blocked nuclear import as assayed by the appearance 
of circular viral DNAs. Still other genes specifically affected 
DNA integration of the HIV-1 genome when depleted.
A third screen, reported by Zhou et al. (2008) in Cell Host & 
Microbe, was similar to the Brass et al. screen in many respects. 
This screen was also performed in HeLa cells expressing CD4 
and harboring a β-galactosidase reporter gene responsive 
to HIV transcription. The cells were transfected with pools of 
 siRNAs directed against about 20,000 genes (~3 siRNAs tar-
geted each gene) and were infected with the HXB2 isolate of 
replication-competent HIV-1 24 hr later. Unlike the two other 
screens, Zhou et al. examined β-galactosidase activity in the 
cells at 48 hr post-infection (to detect the first round of virus 
entry and tat transactivator expression) and again at 96 hr 
post-infection (to detect additional rounds of virus spreading 
into neighboring cells). Zhou et al. identified and confirmed 418 Cell 135, October 31, 2008 ©2008 Elsevier Inc.931 genes as hits. The siRNAs against these genes were then 
tested for their ability to inhibit the release of infectious virus by 
applying the culture supernatant to fresh cells and measuring 
activation of β-galactosidase expression 48 hr later. Depletion 
of 224 of the 931 genes inhibited the release of infectious virus, 
and these genes were also expressed in T cells, the normal 
target of HIV-1. Eighty-four of these genes directly inhibited tat-
mediated activation of the β-galactosidase reporter.
As with the other screens, Zhou et al. grouped the 224 
hits from their screen into several functional classes. These 
included genes likely to be involved in virus entry, tat-mediated 
transcription (such as components of the Mediator complex), 
and the NF-κB signaling pathway. Interestingly, genes involved 
in mitochondrial function (such as those required for oxidative 
phosphorylation) and genes involved in energy metabolism 
(including the Akt kinase, AMP-activated kinase, and compo-
nents of the adipocytokine signaling pathway) were also iden-
tified. For three genes that were characterized based on the 
potential for their gene products to be inhibited by drugs, Zhou 
et al. determined that their depletion blocked virus infection 
before completion of reverse transcription.
At first glance, the results of these three screens seem to be 
in remarkable agreement: In each case, about 200–300 cellu-
lar genes with wide-ranging functions were identified and were 
found to play essential roles at some stage of HIV-1 infection. 
These extremely exciting findings expand the number of host 
cell factors involved in HIV-1 infection at least 5-fold. In prin-
ciple, given that all genes of the human genome have been 
queried by these screens, all of the cellular machinery involved 
in virus replication down to the exact host genes may now be 
in hand. Indeed, virtually every step in the viral life cycle seems 
to involve multiple host proteins. Although the total number of 
host genes required may seem surprisingly high, this is not 
unexpected as similar studies of transposable elements in 
budding yeast have demonstrated that hundreds of genes may 
be involved in the retrotransposition of Ty elements, a process 
similar to retrovirus infection (Aye et al., 2004; Griffith et al., 
2003; Irwin et al., 2005; Scholes et al., 2001).
Closer comparisons of the three screens, however, reveal a 
disconcerting fact: Although all three screens had the same goal, 
they did not recover the same sets of genes. Indeed, there was 
almost no overlap between some pairs of sets. Between the gene 
sets identified in the screens of Brass et al. and König et al. (con-
sisting of about 273 and 295 genes, respectively), there were only 
13 genes in common. Clearly, despite their common aim, these 
screens uncovered wildly different hits. Some of this discrepancy 
can be explained by the different conditions of the three screens 
(Table 1). Brass et al. used HeLa cells and replication-competent 
HIV-1, whereas König et al. used 293T cells and a pseudotyped 
HIV-1 vector. The conditions for siRNA treatment and virus infec-
tion also varied. Brass et al. treated the cells with siRNAs for 72 hr 
before infection and scored viral infectivity 48 hr post-infection. In 
contrast, König et al. treated their 293T cells with siRNAs for 48 
hr and scored the readout 24 hr after infection. These differences 
suggest that the screens may have selectively identified subsets of 
genes involved in different stages of infection. For example, Brass 
et al. may have selectively recovered genes that are involved in 
virus entry via the CD4 receptor, are required for late stages of the 
virus life cycle, or encode relatively stable proteins that required 
longer times to decay after siRNA treatment. In contrast, König et 
al.’s screen may have been biased to recover genes that act only 
in the early steps of infection or encode proteins with short half-
lives. Some of the explanation for the differing results may come 
from the secondary filtering algorithms imposed on the initial hits 
to pare them down to genes already implicated in HIV-1 biology. 
The different filters for “virus relevance” used by each screen may 
impose profound biases, and their ultimate value may prove wildly 
variable.
Comparison of the results from the Brass et al. and Zhou et 
al. screens is also puzzling. Between the two gene sets (about 
273 in Brass et al. and 224 in Zhou et al.), again, there were only 
a few—15 in this case—genes in common. Here the conditions 
of the two screens were very similar. Both were performed in 
HeLa-derived cells, and both used replication-competent HIV-1. 
However, the two screens used different isolates of HIV-1 (the 
IIIB swarm versus the HXB2 clone) with unpredictable effects 
on the final results. In addition, there were differences in siRNA 
treatment times (72 hr versus 24 hr) and the primary readout of 
virus infection (p24 levels versus a tat-dependent reporter), pos-
sibly biasing the proteins identified in each of the two screens 
according to protein half-life or stage of viral infection. Here, also, 
the secondary filters imposed on the screens may have further 
contributed to the differing results. It is possible that many of the 
nonoverlapping genes identified by all three screens are actually 
false positives that are irrelevant to HIV-1 pathogenesis. Clearly, 
more work is necessary to critically validate all of the hits. Also, 
the optimal conditions for this type of siRNA screen still need 
to be determined. Regardless, whatever the explanation for the 
limited overlap among these gene sets, the fact that the results 
of these screens are of enormous interest is indisputable. For 
example, the nuclear import factor TNPO3/Transportin-SR2 
uncovered by the screens has been independently validated 
to play a role in the nuclear import of the HIV-1 preintegration 
complex, PIC (Christ et al., 2008; Luban, 2008). TNPO3 binds 
directly to the viral integrase, and depletion of TNPO3 in the 
host cell blocks entry of PIC into the nucleus as determined by 
micro scopy. Curiously, TNPO3 seems also to be involved in the 
uptake of truncated tRNAs into the nucleus, and it may transpire 
that HIV-1 is hijacking this poorly characterized system to gain 
entry to the nucleus (Zaitseva et al., 2006). The identification of 
other components of the nuclear pore complex, notably Nup153, 
suggests that they are also involved in this process. In addition, 
recovery of Mediator complex components strongly suggests 
that these proteins are essential for HIV-1 transcription. It is also 
of interest that genes connected to the NF-κB signaling path-
way were pinpointed in the screens. Although not unexpected given that NF-κB-binding sites in the viral promoter are impor-
tant for viral gene transcription, the identification of components 
of this pathway is reassuring. Other intriguing leads include 
genes required for ubiquitination, SUMOylation, DNA repair, and 
vesicular transport. Perhaps most exciting among the many hits 
are genes encoding proteins that are involved in mitochondrial 
function and energy production. This indicates that virus infec-
tion and the formation of viral progeny drains the resources of 
host cells, implying that inhibition of energy sources could limit 
virus replication.
Despite the many genes identified in the three screens, it is 
evident that the hunt for host factors is not yet over. The identi-
ties of the hits recovered seem to depend strongly on the condi-
tions and readouts of the screens. Thus, new screens may iden-
tify even more sets of host genes. Indeed, it is likely that even 
these three large-scale screens have missed some important 
players. On balance, how do we evaluate these siRNA-based 
screens in comparison with more conventional genetic screens? 
Clearly, these new methods provide tremendous power. In prin-
ciple, all genes of the genome are being tested, and the effect 
on the gene product—depletion—is likely to be simple and easy 
to interpret. Importantly, this method of depleting gene products 
is perfectly suited to screening in diploid cells, as both alleles 
of a gene are simultaneously suppressed. There are, however, 
some fundamental problems inherent in siRNA screens. Most 
obviously, the cells used in all of these screens were chosen 
for experimental convenience and are not the natural biologi-
cal targets of the virus. Thus, all genes identified in the screens 
will need to be confirmed in the more physiologically relevant 
system of primary T cells. Moreover, any genes that are required 
for infection only in these cells and not in the cells used in the 
screens will simply be missed. Similarly, unannotated genes and 
microRNAs will also not be tested by the screen. Furthermore, 
as siRNAs will deplete only a single gene product at a time, the 
screen may not find those genes whose functions are redun-
dant with other genes. Aside from missing certain categories 
of genes, siRNAs often have off-target effects on unexpected 
genes and could thus result in false positive hits. There may also 
be false negatives in cases when siRNAs may not have sufficient 
activity against mRNAs. Alternatively, false negatives can arise 
when a gene product is so stable that it decreases too slowly 
for the loss-of-function phenotype to be assayed even though 
its mRNA is efficiently depleted. For example, the key host fac-
tor LEDGF (lens epithelium-derived growth factor), which is 
known to partner with the HIV-1 integrase to establish proviral 
DNA, was not identified in any of the three screens. However, 
it is known that defects in viral infection are difficult to detect in 
LEDGF knockdown cells, possibly due to low levels of the pro-
tein remaining even after efficient mRNA depletion (Llano et al., 
2004; Maertens et al., 2003). The secondary filters imposed on 
the screens also contribute to their limitations. The filters will dis-
card those genes whose depletion is lethal or toxic to the host 
cell, even if they play essential roles in promoting virus infection. 
However, this is a limitation that is shared with most mutational 
studies and could possibly be overcome by the use of a condi-
tionally active siRNA library. Lastly, the siRNA screens are likely 
to identify only those genes whose depletion confers recessive, 
loss-of-function, or hypomorphic effects. Unlike a conventional Cell 135, October 31, 2008 ©2008 Elsevier Inc. 419
mutagenesis screen, the full range of mutations, such as over-
expression or dominant mutations, are not likely to be found. In 
spite of these many limitations, siRNA screens still offer huge 
promise when used as a primary genetic screen. Indeed, they 
give the molecular biologists among us much to chew on.
No doubt, such siRNA screens can also be used to elucidate 
host factors required for infection by other isolates of HIV and 
SIV, as well as nonretroviruses. Indeed, similar screens have 
been performed in human cells to identify host genes impor-
tant for infection by West Nile virus (Krishnan et al., 2008) and 
in cells of the fruit fly to study cellular factors important for the 
replication of influenza virus (Hao et al., 2008). Like the HIV-1 
screens, these surveys identified hundreds of genes. Satisfy-
ingly, the genes identified were involved in processes similar to 
those found in the HIV-1 screens, such as protein trafficking, 
ubiquitination, and transcription. The functions of the human 
homologs of the Drosophila genes, which were tested for the 
effects of their depletion on influenza virus pathogenesis, were 
particularly striking. These experiments confirmed the impor-
tance of genes involved in energy metabolism and in the export 
of RNAs from the nucleus to the cytoplasm. The broad over-
lap of critical host cell functions required for viral replication 
across such diverse virus families raises the prospect of devel-
oping antiviral interventions that could simultaneously act on 
many of these viruses, a holy grail of antiviral therapy.
The use of these cellular genes as targets for antiviral drugs is 
already becoming a reality. The key hope is that targeting host 
cell gene products that do not have the mutagenic potential 
of viral genes will minimize the acquisition of drug resistance 
and will provide long-lasting blocks to virus replication. Indeed, 
some of the most promising anti-HIV-1 drugs already approved 
or in clinical trials are targeted not against a viral protein but 
against CCR5, the cellular coreceptor for virus entry. These 
siRNA screens have provided dozens, if not hundreds, of new 
cellular targets for slowing or stopping the replication of HIV-1 
and other lethal viruses. Such efforts should be spurred by the 
assembly of a database containing host genes implicated in 
HIV replication, which is currently underway (F.D. Bushman, 
personal communication).420 Cell 135, October 31, 2008 ©2008 Elsevier Inc.AcKnowledgmentS
This work was supported by PHS grant R37 CA 30488 from the National Can-
cer Institute. S.P.G. is an Investigator of the Howard Hughes Medical Institute.
RefeRenceS
Aye, M., Irwin, B., Beliakova-Bethell, N., Chen, E., Garrus, J., and Sand-
meyer, S. (2004). Genetics 168, 1159–1176.
Brass, A.L., Dykxhoorn, D.M., Benita, Y., Yan, N., Engelman, A., Xavier, 
R.J., Lieberman, J., and Elledge, S.J. (2008). Science 319, 921–926.
Christ, F., Thys, W., De Rijck, J., Gijsbers, R., Albanese, A., Arosio, D., 
Emiliani, S., Rain, J.C., Benarous, R., Cereseto, A., and Debyser, Z. (2008). 
Curr. Biol. 18, 1192–1202.
Griffith, J.L., Coleman, L.E., Raymond, A.S., Goodson, S.G., Pittard, W.S., 
Tsui, C., and Devine, S.E. (2003). Genetics 164, 867–879.
Hao, L., Sakurai, A., Watanabe, T., Sorensen, E., Nidom, C.A., Newton, 
M.A., Ahlquist, P., and Kawaoka, Y. (2008). Nature 454, 890–894.
Irwin, B., Aye, M., Baldi, P., Beliakova-Bethell, N., Cheng, H., Dou, Y., Liou, 
W., and Sandmeyer, S. (2005). Genome Res. 15, 641–654.
König, R., Zhou, Y., Elleder, D., Diamond, T.L., Bonamy, G.M.C., Irelan, 
J.T., Chiang, C.-y., Tu, B.P., De Jesua, P.D., Lilley, C.E., et al. (2008). Cell 
135, 49–60.
Krishnan, M.N., Ng, A., Sukumaran, B., Gilfoy, F.D., Uchil, P.D., Sultana, H., 
Brass, A.L., Adametz, R., Tsui, M., Qian, F., et al. (2008). Nature 454, 1–6.
Llano, M., Vanegas, M., Fregoso, O., Saenz, D., Chung, S., Peretz, M., and 
Poeschla, E.M. (2004). J. Virol. 78, 9524–9537.
Luban, J. (2008). Curr. Biol. 18, R710–R713.
Maertens, G., Cherepanov, P., Pluymers, W., Busschots, K., De Cler-
cq, E., Debyser, Z., and Engelborghs, Y. (2003). J. Biol. Chem. 278, 
33528–33539.
Scholes, D.T., Banerjee, M., Bowen, B., and Curcio, M.J. (2001). Genetics 
159, 1449–1465.
Zaitseva, L., Myers, R., and Fassati, A. (2006). PLoS Biol. 4, e332. 10.1371/
journal.pbio.0040332.
Zhou, H., Xu, M., Huang, Q., Gates, A.T., Zhang, X.D., Stec, E., Ferrer, M., 
Strulovici, B., Hazuda, D.J., and Espeseth, A.S. (2008). Cell Host Microbe. 
Published online October 30, 2008. 10.1016/j.chom.2008.10.004.
